Magnetic Resonance Myocardial Stress Perfusion in Pediatric Patients with Cardiovascular Disease

NCT06641843 | Enrolling By Invitation

• 1 other identifier: WestChinaSUH2024223
• Study Type: observational
• Target: 240
• Locations: 1 country
• Sites: 1

Brief Summary

the goal of this observational study is to evaluate myocardial ischemia and myocardial microcirculation dysfunction in children with cardiovascular disease by myocardial stress perfusion imaging. During their disease progress, participants will undergo myocardial stress perfusion, laboratory tests when hospitalization and follow-up, and the baseline data will be collected in the admission. all the above examination data will be analysed to identify early subclinical myocardial changes and evaluate the value of magnetic resonance myocardial stress perfusion in predicting prognosis.

Conditions

Kawasaki Disease; Cardiovascular Disease; Anomalous Origin of Coronary Artery

Outcome Measures

Primary Outcomes (1)

• Major adverse cardiovscualr events

  Major adverse cardiovascular events including cardiac death, transient ischemic attack or stroke, myocardial infarction, arrhythmia, heart failure, severe valvular disease, percutaneous coronary intervention, coronary artery bypass graft, and other cardiovascular surgery.

  10 years after the onset

Study Arms (1)

patients diagnosed with cardiovascular disease

Patients diagnosed with cardiovascular disease, including Kawasaki disease, anomalous origin of coronary artery, postoperative congenital heart diseases

Eligibility Criteria

• Age: Up to 18 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

From September 2024 to Jaunary 2034, pediatric patients diagnosed with cardiovascular disease were prospectively recruited from West China Second University Hospital, Sichuan University.

You may qualify if:

• Patients diagnosed with cardiovascular disease, including Kawasaki disease, anomalous origin of coronary artery, postoperative congenital heart disease.

You may not qualify if:

• Mental abnormalities or poor compliance ; heart, kidney and other important organs were seriously incomplete.
• MRI examination contraindications ; gadolinium contrast agent contraindications ; claustrophobia.

Sponsors & Collaborators

• West China Second University Hospital: lead

Study Sites (1)

West China Second University Hospital, Sichuan University.

Chengdu, Sichuan, China

Location

Related Publications (8)

• Zhou W, Lee JCY, Leung ST, Lai A, Lee TF, Chiang JB, Cheng YW, Chan HL, Yiu KH, Goh VK, Pennell DJ, Ng MY. Long-Term Prognosis of Patients With Coronary Microvascular Disease Using Stress Perfusion Cardiac Magnetic Resonance. JACC Cardiovasc Imaging. 2021 Mar;14(3):602-611. doi: 10.1016/j.jcmg.2020.09.034. Epub 2020 Nov 25.

  PMID: 33248966 BACKGROUND

• Erbel C, Mukhammadaminova N, Gleissner CA, Osman NF, Hofmann NP, Steuer C, Akhavanpoor M, Wangler S, Celik S, Doesch AO, Voss A, Buss SJ, Schnabel PA, Katus HA, Korosoglou G. Myocardial Perfusion Reserve and Strain-Encoded CMR for Evaluation of Cardiac Allograft Microvasculopathy. JACC Cardiovasc Imaging. 2016 Mar;9(3):255-66. doi: 10.1016/j.jcmg.2015.10.012.

  PMID: 26965729 BACKGROUND

• Shaw JL, Nelson MD, Wei J, Motwani M, Landes S, Mehta PK, Thomson LEJ, Berman DS, Li D, Bairey Merz CN, Sharif B. Inverse association of MRI-derived native myocardial T1 and perfusion reserve index in women with evidence of ischemia and no obstructive CAD: A pilot study. Int J Cardiol. 2018 Nov 1;270:48-53. doi: 10.1016/j.ijcard.2018.06.086. Epub 2018 Jun 22.

  PMID: 30041981 BACKGROUND

• Park SM, Wei J, Cook-Wiens G, Nelson MD, Thomson L, Berman D, Handberg E, Petersen J, Anderson D, Pepine CJ, Merz CNB. Left ventricular concentric remodelling and functional impairment in women with ischaemia with no obstructive coronary artery disease and intermediate coronary flow reserve: a report from the WISE-CVD study. Eur Heart J Cardiovasc Imaging. 2019 Aug 1;20(8):875-882. doi: 10.1093/ehjci/jez044.

  PMID: 30904924 BACKGROUND

• Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O'Connor RE, Ross MA, Shaw LJ. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Nov 30;144(22):e368-e454. doi: 10.1161/CIR.0000000000001030. Epub 2021 Oct 28.

  PMID: 34709928 BACKGROUND

• Ferrari R, Rosano G. 2019 guidelines for the diagnosis and management of chronic coronary syndromes: congratulations and criticism. Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):331-332. doi: 10.1093/ehjcvp/pvaa006. No abstract available.

  PMID: 32154890 BACKGROUND

• Aetesam-Ur-Rahman M, Brown AJ, Jaworski C, Giblett JP, Zhao TX, Braganza DM, Clarke SC, Agrawal BSK, Bennett MR, West NEJ, Hoole SP. Adenosine-Induced Coronary Steal Is Observed in Patients Presenting With ST-Segment-Elevation Myocardial Infarction. J Am Heart Assoc. 2021 Jul 6;10(13):e019899. doi: 10.1161/JAHA.120.019899. Epub 2021 Jun 30.

  PMID: 34187187 BACKGROUND

• Patel AR, Salerno M, Kwong RY, Singh A, Heydari B, Kramer CM. Stress Cardiac Magnetic Resonance Myocardial Perfusion Imaging: JACC Review Topic of the Week. J Am Coll Cardiol. 2021 Oct 19;78(16):1655-1668. doi: 10.1016/j.jacc.2021.08.022.

  PMID: 34649703 BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

The whole boold including blood cell and plasma will be collected for laboratory test.

MeSH Terms

Conditions

Mucocutaneous Lymph Node Syndrome; Cardiovascular Diseases

Condition Hierarchy (Ancestors)

Vasculitis; Vascular Diseases; Lymphatic Diseases; Hemic and Lymphatic Diseases; Skin Diseases, Vascular; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: October 8, 2024
• First Posted: October 15, 2024
• Study Start: September 1, 2024
• Primary Completion (Estimated): January 1, 2034
• Study Completion (Estimated): September 30, 2034
• Last Updated: October 15, 2024

Record last verified: 2024-09

Locations

CN (1)